Risk Of Developing Liver Cancer After HCV Treatment

Tuesday, August 6, 2013

Hepatitis C Clinical Trials Now Recruiting - Sofosbuvir Trial Updates For July 2013

What Is A Clinical Study?
Take The Time To Learn About Clinical Studies

Clinical Trials.gov - Hepatitis
ClinicalTrials.gov provides regularly updated information about federally and privately supported clinical research in human volunteers. Site gives information about a trial's purpose, who may participate, locations, and phone numbers for more details.
View all Trial Updates @ ClinicalTrials.gov: last 30 days

CenterWatch - U.S. and International
U.S. Hepatitis Clinical Trials Listed By City And State
View all Trial Updates @ CenterWatch

Articles Of Interest
COMMENTARY ON: Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. 

Both Simeprevir and Sofosbuvir Likely Approved by 2014-Clinical/Ethical/Pharmacoeconomic Dilemmas Loom 

Sofosbuvir -FDA Grants Priority Review, Approval Set For December

Hepatitis C Therapy Update 2013-What About Interferon-free Regimens?

____________________________________________________

Sofosbuvir Trial Updates For July 2013
____________________________________________________

Phase 3 Study of Sofosbuvir and Ribavirin

This study is currently recruiting participants

Purpose
Sofosbuvir and ribavirin in Japanese subjects with chronic Hepatitis C.

Study Type:Interventional
Study Design:Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title:A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Treatment-Naïve and Treatment-Experienced Japanese Subjects With Chronic Genotype 2 HCV Infection

Responsible Party:Gilead Sciences
ClinicalTrials.gov Identifier:NCT01910636     History of Changes
Other Study ID Numbers:GS-US-334-0118
Study First Received:July 23, 2013
Last Updated:July 25, 2013
Health Authority:Japan: Pharmaceuticals and Medical Devices Agency

____________________________________________________

Phase 2 Study of SOF+GS-5816 in Treatment Experienced Subjects With Chronic Genotype 3 HCV

This study is currently recruiting participants

Purpose
This study will evaluate sofosbuvir (SOF)+GS-5816 for the treatment of chronic genotype 3 Hepatitis C Virus (HCV) infection in treatment experienced subjects.

Study Type:Interventional
Study Design:Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title:A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Experienced Subjects With Chronic HCV Infection
Responsible Party:Gilead Sciences
ClinicalTrials.gov Identifier:NCT01909804     History of Changes
Other Study ID Numbers:GS-US-342-0109
Study First Received:July 17, 2013
Last Updated:July 26, 2013
Health Authority:United States: Food and Drug Administration

____________________________________________________
 
Open-Label Study of GS-7977+ Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

This study is currently recruiting participants

Purpose
Open label study of GS-7977 in combination with ribavirin (RBV) with or without Peginterferon Alfa-2a (PEG) in adults with chronic HCV who participated in a prior Gilead HCV study and have not achieved SVR.

Study Type:Interventional
Study Design:Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title:An Open-Label Study of GS-7977 + Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
Responsible Party:Gilead Sciences
ClinicalTrials.gov Identifier:NCT01625338     History of Changes
Other Study ID Numbers:GS-US-334-0109
Study First Received:June 7, 2012
Last Updated:June 19, 2013
Health Authority:United States: Food and Drug Administration
____________________________________________________

This study is currently recruiting participants

Purpose
This is a research study to evaluate the safety, tolerability, and anti-viral activity of sofosbuvir with ribavirin in Egyptian adults with genotype 4 hepatitis C infection

Study Type:

Interventional
Study Design:Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title:A Phase 3, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naïve and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 HCV Infection.
Responsible Party:Gilead Sciences
ClinicalTrials.gov Identifier:NCT01838590     History of Changes
Other Study ID Numbers:GS-US-334-0138
Study First Received:April 15, 2013
Last Updated:May 22, 2013
Health Authority:United States: Food and Drug Administration
____________________________________________________

A Phase 2a Study of GS-6624 in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis

This study is currently recruiting participants.

Purpose
This is an open label, exploratory study of GS-6624 in adult subjects infected with HIV, HCV, or co-HIV/HCV with histological evidence of liver fibrosis. Subjects will receive 700 mg IV GS-6624 every 2 weeks for a total of 24 weeks (12 infusions) while continuing on standard therapy for HIV (HIV-infected subjects only).

Study Type:Interventional
Study Design:Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title:A Phase 2a Study of an Anti-LOXL2 Monoclonal Antibody (GS-6624) in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis
Responsible Party:Gilead Sciences
ClinicalTrials.gov Identifier:NCT01707472     History of Changes
Other Study ID Numbers:GS-US-321-0107
Study First Received:September 11, 2012
Last Updated:June 4, 2013
Health Authority:United States: Food and Drug Administration
____________________________________________________

A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

This study is currently recruiting participants.

Purpose
This is a Phase 1 Open-Label, Parallel-Group, Single-Dose Study to evaluate the Pharmacokinetics of GS-5816 in subjects with normal hepatic function and moderate or severe hepatic impairment.

Study Type:Interventional
Study Design:Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title:A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
 
Responsible Party:Gilead Sciences
ClinicalTrials.gov Identifier:NCT01817985     History of Changes
Other Study ID Numbers:GS-US-281-0112
Study First Received:March 20, 2013
Last Updated:July 17, 2013
Health Authority:United States: Food and Drug Administration
 
____________________________________________________

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects

This study is currently recruiting participants.

Purpose
This is an Open-label Phase 3 study in subjects with chronic Genotype 1, 2, 3, and 4 HCV-infection who are co-infected with HIV-1. A total of 220 HCV subjects who are co-infected with HIV-1 will be enrolled into a single arm and treated with oral SOF 400 mg QD plus weight based RBV (1000 or 1200 mg/day) BID for 12 weeks or 24 weeks. The study population will include HCV genotype 1, 2, 3, and 4 HCV treatment naive subjects (including IFN ineligible) and HCV genotype 2 and 3 HCV treatment experienced subjects who have failed prior therapy with PEG/RBV. Approximately 20% of the subjects enrolled will have evidence of compensated cirrhosis at Screening.

Study Type:Interventional
Study Design:Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title:A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects

Responsible Party:Gilead Sciences
ClinicalTrials.gov Identifier:NCT01783678     History of Changes
Other Study ID Numbers:GS-US-334-0124
Study First Received:January 31, 2013
Last Updated:April 9, 2013
Health Authority:United States: Food and Drug Administration
____________________________________________________

Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection.

This study is currently recruiting participants.

Purpose
The purpose of this study is to determine the effectiveness and safety of sofosbuvir plus ribavirin administered for 16 weeks and 24 weeks in patients with chronic genotype 1 or 3 HCV infection

Study Type:Interventional
Study Design:Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title:A Phase 3b, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection.
 
Responsible Party:Gilead Sciences
ClinicalTrials.gov Identifier:NCT01896193     History of Changes
Other Study ID Numbers:GS-US-334-0119
Study First Received:July 2, 2013
Last Updated:July 8, 2013
Health Authority:Russia: Ministry of Health of the Russian Federation
____________________________________________________

Phase 2 Study of SOF+GS-5816 in Treatment Naive Subjects With Chronic HCV

This study is ongoing, but not recruiting participants.

Purpose
This study will evaluate sofosbuvir (SOF)+GS-5816 for the treatment of Hepatitis C Virus (HCV) infection.
Study Type:Interventional
Study Design:Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title:A Phase 2, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Sofosbuvir+ GS-5816 for 12 Weeks in Treatment-naive Subjects With Chronic HCV Infection
Responsible Party:Gilead Sciences
ClinicalTrials.gov Identifier:NCT01858766     History of Changes
Other Study ID Numbers:GS-US-342-0102
Study First Received:May 10, 2013
Last Updated:July 22, 2013
Health Authority:United States: Food and Drug Administration
____________________________________________________

Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

This study is ongoing, but not recruiting participants.

Purpose
The purpose of this study is to evaluate the safety, tolerability and antiviral efficacy of Sofosbuvir/Ledipasvir (FDC) with or without RBV administered for 8 weeks and Sofosbuvir/Ledipasvir (FDC) administered for 12 weeks in treatment-naive subjects with chronic genotype 1 HCV infection.

Study Type:Interventional
Study Design:Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title:A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination (FDC) +/- Ribavirin for 8 Weeks and Sofosbuvir/Ledipasvir Fixed-Dose Combination (FDC) for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection

Responsible Party:Gilead Sciences
ClinicalTrials.gov Identifier:NCT01851330     History of Changes
Other Study ID Numbers:GS-US-337-0108
Study First Received:May 3, 2013
Last Updated:July 19, 2013
Health Authority:United States: Food and Drug Administration
____________________________________________________

Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Subjects With Chronic Genotype 1, 2, or 3 HCV Infection

This study is currently recruiting participants.

Purpose
The purpose of this study is to evaluate the safety, tolerability and antiviral efficacy of combination therapy with sofosbuvir (SOF)-containing regimens for the treatment of chronic hepatitis C virus (HCV) infection.

Study Type:Interventional
Study Design:Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title:A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection


Responsible Party:Gilead Sciences
ClinicalTrials.gov Identifier:NCT01826981     History of Changes
Other Study ID Numbers:GS-US-337-0122
Study First Received:April 1, 2013
Last Updated:April 4, 2013
Health Authority:New Zealand: Medsafe

____________________________________________________

Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C

Expanded access is currently available for this treatment.

Purpose
This is a single arm, open-label study which will be opened at specific clinical sites at the request of an investigator for the treatment of individual subjects for whom there are no other treatment options. Subjects will be treated for 24 weeks with sofosbuvir (400mg QD) with RBV; pegylated interferon may be added at the discretion of the investigator.

Study Type:Expanded Access     What is Expanded Access?
Official Title:An Expanded Access Phase 2 Study of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon for 24 Weeks in Subjects Who Have Undergone Liver Transplantation and Who Have Aggressive, Recurrent Hepatitis C Infection
 
Responsible Party:Gilead Sciences
ClinicalTrials.gov Identifier:NCT01779518     History of Changes
Other Study ID Numbers:GS-US-334-0139
Study First Received:January 23, 2013
Last Updated:June 14, 2013
Health Authority:United States: Food and Drug Administration
United States: Institutional Review Board

No comments:

Post a Comment